Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) Profiles of TNP-2092 Administered Via Intra-articular (IA) Injection on a Background of Antibiotic Treatment in Adult Participants With Early Postoperative or Acute Hematogenous Prosthetic Joint Infection (PJI) After Knee Arthroplasty, Without Debridement, or in Participants With Chronic PJI Requiring Long-term Antibiotic Suppressive Treatment.

NCT07858916 is registered in ClinicalTrials.gov with TenNor Therapeutics (Zhongshan) Limited as lead sponsor.

NCT NCT07858916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07858916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) Profiles of TNP-2092 Administered Via Intra-articular (IA) Injection on a Background of Antibiotic Treatment in Adult Participants With Early Postoperative or Acute Hematogenous Prosthetic Joint Infection (PJI) After Knee Arthroplasty, Without Debridement, or in Participants With Chronic PJI Requiring Long-term Antibiotic Suppressive Treatment.
Lead sponsor
TenNor Therapeutics (Zhongshan) Limited
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
March 31, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prosthetic joint infection (pji)